Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in the stem cells that drive high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
